Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification

Autor:	Hironao Okubo, Hitoshi Ando, Shunsuke Nakamura, Yusuke Takasaki, Koichi Ito, Yuka Fukuo, Kenichi Ikejima, Hiroyuki Isayama
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	aldolase cabozantinib dose modification hepatocellular carcinoma muscle injury relative dose intensity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Druh dokumentu:	article
ISSN:	2045-7634
DOI:	10.1002/cam4.70222
Popis:	Abstract Aim To investigate the outcomes of cabozantinib in patients with unresectable hepatocellular carcinoma (uHCC), focusing on dose setting and modification. Methods We retrospectively analyzed 34 Japanese patients who received cabozantinib for uHCC. Trough concentrations (Ctrough) of cabozantinib were also measured weekly for 6 weeks in the 18 patients. Results Sixteen patients received ≥40 mg (high‐dose group), and 18 patients received 20 mg (low‐dose group). Dose escalations were performed in 27.8% of the patients in the low‐dose group. Although median duration of the first dose reduction or interruption in the low‐dose group was twice that in the high‐dose group (28 vs. 14 days, p
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/bd189ccd8e1748df98a3f1cc1ca5db23 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.